Laurus Labs’ wholly owned subsidiary -- Laurus Synthesis (LSPL) has underwent the United States Food and Drug Administration (USFDA) inspection for the manufacturing facility in Parawada, Anakapalli, near Visakhapatnam, Andhra Pradesh. The inspection was conducted from December 4, 2023 to December 12, 2023. It has been issued a Form 483 with five observations and the Company will address the observations within stipulated timelines.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
